A Phase II study of intravenous exatecan mesylate (DX‐8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma

Abstract

Exatecan mesylate had moderate activity in patients with anthracycline-refractory and taxane-refractory, metastatic breast carcinoma. The toxicity profile of exatecan mesylate was acceptable, and it appeared to have linear PK characteristics on the basis of multiple dose administration.